Biopharmx Corp (BPMX) Earning Somewhat Positive News Coverage, Study Shows
Headlines about Biopharmx Corp (NYSE:BPMX) have been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Biopharmx Corp earned a coverage optimism score of 0.15 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 46.6141368914888 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the news headlines that may have effected Accern’s rankings:
- ETFs with exposure to BioPharmX Corp. : November 7, 2017 (finance.yahoo.com)
- Zacks: Analysts Set $2.78 Price Target for Biopharmx Corp (BPMX) (americanbankingnews.com)
- Glowing Stock’s Review: BioPharmX Corporation (NYSE: BPMX) – Alpha Beta Stock (alphabetastock.com)
- BioPharmX Corporation (BPMX) -58.75% off from 200- SMA – Voice Of Analysts (analystsbuzz.com)
- Eye-Catching Hot Stocks: BioPharmX Corporation (NYSE: BPMX) – Alpha Beta Stock (alphabetastock.com)
Biopharmx Corp (NYSE:BPMX) traded up $0.04 during mid-day trading on Tuesday, reaching $0.21. The company’s stock had a trading volume of 3,009,264 shares, compared to its average volume of 1,450,000. Biopharmx Corp has a twelve month low of $0.16 and a twelve month high of $0.90.
Biopharmx Corp Company Profile
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.